Cell Therapy Preclinical Licensing Benchmarks
Deal economics across 16 transactions with 10 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$91M
10 deals with terms
Median Total Value
$941M
Upfront + milestones
Royalty Range
5.8%--12%
Average low--high
Deal Count
16
2019--2026
The median upfront payment for preclinical cell therapy licensing deals is $91M, based on 10 deals with disclosed terms from 2019--2026. Total deal values (including milestones) reach a median of $941M. Royalty rates typically range from 5.8% to 12%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Capstan Therapeutics | AbbVie | 2025 | $2.1B | $2.1B |
| Prime Medicine | Bristol Myers Squibb | 2024 | $110M | $3.6B |
| Umoja Biopharma | Biogen | 2024 | $95M | $856.477396M |
Showing 3 of 10 deals with disclosed terms. Full comp set available in the report.
Full cell-therapy Preclinical Comp Set
Get the complete analysis -- 10 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific cell therapy asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2019--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.